CORD-19:3c1f47a07aaf0e393dee9fbd08596a4b9f4f0a03 / 248814-249059 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1930","span":{"begin":0,"end":245},"obj":"Sentence"},{"id":"T11875","span":{"begin":0,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Two randomised, double-blind phase 3 cIAI trials compared intravenous (IV) doripenem (500 mg q8h) with IV meropenem (500 mg q8h), with an option to switch to amoxicillin/clavulanate for both treatment arms after 9 doses of IV study drug therapy."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T29","span":{"begin":0,"end":245},"obj":"Sentence"}],"text":"Two randomised, double-blind phase 3 cIAI trials compared intravenous (IV) doripenem (500 mg q8h) with IV meropenem (500 mg q8h), with an option to switch to amoxicillin/clavulanate for both treatment arms after 9 doses of IV study drug therapy."}